Company continues to focus on expanding its reach and organic growth, expense control, and laying foundation for advancing leadership position in genetic testing and precision medicine SALT LAKE CITY, ...

B, as a powerful regulator that enhances wheat’s regeneration efficiency by balancing cytokinin levels and activating regeneration-related genes.

Paul J. Diaz, President and Chief Executive Officer: “In the midst of the COVID-19 pandemic, we continued to support our patients and healthcare providers with critical genetic insights needed to ...

Agrobacterium-mediated genetic transformation of an elite Indian genotype (Bikaneri Nerma) of cotton (Gossypium hirsutum L.) was achieved using shoot apical meristems isolated from seedlings as ...

In a report released on August 7, Puneet Souda from Leerink Partners maintained a Buy rating on Myriad Genetics (MYGN – Research Report), with a price target of $35.00. Puneet Souda has given his Buy ...

SALT LAKE CITY, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced the substantial completion of its strategic ...

A new research perspective was published in Oncotarget's Volume 15 on January 24, 2024, entitled, "Genetic alterations in thyroid cancer mediating both resistance to BRAF inhibition and anaplastic ...

SALT LAKE CITY, July 19, 2022 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will host an Investor Day on Aug. 11, 2022, providing a ...